open access

Vol 6, No 1 (2017)
Original articles (submitted)
Published online: 2017-06-20
Get Citation

Antidiabetic medications use and cancer risk in type 2 diabetes

Mariusz Dąbrowski, Elektra Szymańska-Garbacz, Zofia Miszczyszyn, Tadeusz Dereziński, Leszek Czupryniak
DOI: 10.5603/DK.2017.0004
·
Clinical Diabetology 2017;6(1):17-25.

open access

Vol 6, No 1 (2017)
Original articles (submitted)
Published online: 2017-06-20

Abstract

Introduction. The risk of several types of cancer is increased in type 2 diabetes mellitus (T2DM). Impact of antidiabetic medications on this risk is still a matter of controversies. The aim of our observational study was to evaluate the risk of cancer occurrence associated with the most frequently used antidiabetic agents.

Material and methods. 213 patients (118 women) with T2DM who developed cancer while treated for diabetes and 213 subjects with T2DM without cancer, matched by age and gender in a 1:1 case-control manner were included. Date of cancer diagnosis was considered as index time, and for each comparator data from the same calendar time were used.

Results. Both in the univariate and in multiple logistic regression analysis metformin use was associated with reduced cancer risk, while elevated risk associated with insulin use was significant only in univariate but not in multiple logistic regression analysis. Insulin and sulfonylurea derivatives in monotherapy were associated with significantly higher cancer risk compared to metformin monotherapy, while in combination with metformin this risk was attenuated to non-significant level.

Conclusion. Our study suggests protective effect of metformin and potentially negative impact of insulin and sulfonylurea derivatives on cancer risk. These findings should be interpreted with caution, due to relatively small study group. Nevertheless, to minimize cancer risk associated with antidiabetic medications’ use, metformin should be continued as long as medically acceptable and it should be combined with insulin or SU to neutralize risk associated with using either of the latter drugs in monotherapy.

Abstract

Introduction. The risk of several types of cancer is increased in type 2 diabetes mellitus (T2DM). Impact of antidiabetic medications on this risk is still a matter of controversies. The aim of our observational study was to evaluate the risk of cancer occurrence associated with the most frequently used antidiabetic agents.

Material and methods. 213 patients (118 women) with T2DM who developed cancer while treated for diabetes and 213 subjects with T2DM without cancer, matched by age and gender in a 1:1 case-control manner were included. Date of cancer diagnosis was considered as index time, and for each comparator data from the same calendar time were used.

Results. Both in the univariate and in multiple logistic regression analysis metformin use was associated with reduced cancer risk, while elevated risk associated with insulin use was significant only in univariate but not in multiple logistic regression analysis. Insulin and sulfonylurea derivatives in monotherapy were associated with significantly higher cancer risk compared to metformin monotherapy, while in combination with metformin this risk was attenuated to non-significant level.

Conclusion. Our study suggests protective effect of metformin and potentially negative impact of insulin and sulfonylurea derivatives on cancer risk. These findings should be interpreted with caution, due to relatively small study group. Nevertheless, to minimize cancer risk associated with antidiabetic medications’ use, metformin should be continued as long as medically acceptable and it should be combined with insulin or SU to neutralize risk associated with using either of the latter drugs in monotherapy.

Get Citation

Keywords

type 2 diabetes, cancer, metformin, sulfonylurea derivatives, insulin

About this article
Title

Antidiabetic medications use and cancer risk in type 2 diabetes

Journal

Clinical Diabetology

Issue

Vol 6, No 1 (2017)

Pages

17-25

Published online

2017-06-20

DOI

10.5603/DK.2017.0004

Bibliographic record

Clinical Diabetology 2017;6(1):17-25.

Keywords

type 2 diabetes
cancer
metformin
sulfonylurea derivatives
insulin

Authors

Mariusz Dąbrowski
Elektra Szymańska-Garbacz
Zofia Miszczyszyn
Tadeusz Dereziński
Leszek Czupryniak

Important: This website uses cookies.tanya dokter More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Czasopismo Diabetologia Kliniczna dostęne jest również w Ikamed - księgarnia medyczna

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl